Givastomig - I-MAB Biopharma
Alternative Names: ABL-111; CD4B; Giva; TJ-033721; TJ-CD4B; TJ-CLDN4BLatest Information Update: 23 Sep 2024
At a glance
- Originator I-MAB Biopharma
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Adenocarcinoma; Gastric cancer; Pancreatic cancer; Solid tumours
- No development reported Colorectal cancer
Most Recent Events
- 23 Sep 2024 Updated efficacy, adverse events and PK data from a phase I trial in Solid-tumours released by I-Mab Biopharma
- 13 Sep 2024 Pharmacokinetics, efficacy and adverse events data from the phase I trial in Solid tumours presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
- 04 Sep 2024 Phase-I development in Solid-tumours (Late-stage disease, Metastatic disease) in USA (Parenteral) (NCT04900818)